TREA

79381493 - PLEQSTELB

Follow

Information

  • Trademark
  • 79381493
  • Serial Number
    79381493
  • Filing Date
    September 01, 2023
    10 months ago
  • Transaction Date
    June 03, 2024
    25 days ago
  • Status Date
    May 16, 2024
    a month ago
  • Location Date
    May 06, 2024
    a month ago
  • Status Code
    641
  • Current Location
    TMO LAW OFFICE 112 - EXAMINING ATTORNEY ASSIGNED
    Employee Name
    PARKS, KIMBERLY L
  • Attorney Docket Number
    034845.394
    Attorney Name
    Scott D. Woldow
    Law Office Assigned Location Code
    M30
  • Owners
Information
Mark Drawing Code
4
Mark Identification
PLEQSTELB
Case File Statements
  • GS0051: Pharmaceutical preparations for cardiovascular diseases, illnesses, and conditions; Pharmaceutical preparations for infusion therapy; pharmaceutical preparations for novel, plasma derived apolipoprotein A-I infusion therapy; pharmaceutical preparations for novel apolipoprotein A-I infusion therapy to potentially reduce the risk of recurrent major adverse cardiovascular events, MACE, in patients within 90 days of an acute myocardial infarction, AMI, with a sustained benefit for 365 days; Pharmaceutical preparations for acute myocardial infarction, AMI; Pharmaceutical preparations for cardiovascular diseases; pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD
Case File Event Statements
  • 10/19/2023 - 8 months ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR
  • 10/20/2023 - 8 months ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 10/24/2023 - 8 months ago
    3 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 2/15/2024 - 4 months ago
    4 - TEAS VOLUNTARY AMENDMENT RECEIVED Type: PARI
  • 4/30/2024 - a month ago
    5 - ASSIGNED TO EXAMINER Type: DOCK
  • 5/6/2024 - a month ago
    6 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 5/7/2024 - a month ago
    7 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 6/3/2024 - 25 days ago
    10 - REFUSAL PROCESSED BY IB Type: RFNP
  • 5/16/2024 - a month ago
    8 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 5/16/2024 - a month ago
    9 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS